Life
Gilead to buy cancer biotech Tubulis for more than $3 billion
Strategic angle: Gilead is acquiring the German biotech Tubulis, enhancing its oncology pipeline with a significant investment.
editorial-staff
1 min read
Updated 4 days ago
Gilead Sciences has announced its acquisition of Tubulis, a German biotechnology company specializing in cancer therapies, for a reported value exceeding $3 billion.
This acquisition is aimed at strengthening Gilead's oncology portfolio, which is critical for the company's growth strategy in the competitive biotech landscape.
The integration of Tubulis' innovative cancer therapies is expected to enhance Gilead's existing capabilities and expand its market reach in oncology.